opioids and alcoholics with the G allele had reduced relapse rates when treated with naltrexone. Additional connections between OPRM1 and treatments for opioid and nicotine addiction are also promising, but require further study. Clear definitions of the phenotypes and ethnicities involved in these future analyses will be essential, as even minor variations in either factor could compromise the ability to replicate previous findings [119]. By confirming the pharmacogenetic effects of OPRM1 polymorphisms and using those findings to guide treatment decisions, patients can be prescribed the therapeutic options with the best efficacy and the greatest tolerability.
